Business Context and Reporting Period
This Form 8-K reports on the 2023 Annual Meeting of Stockholders held by GlycoMimetics, Inc. on May 19, 2023. The filing details the results of three proposals submitted to security holders. Note: The request metadata lists "CRESCENT BIOPHARMA, INC.", but the filing text explicitly identifies the registrant as GlycoMimetics, Inc.
Key Financial Metrics
This filing is a Current Report regarding corporate governance and does not contain financial performance data. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Voting Results
Of the 64,245,224 shares outstanding, 50,862,969 shares (79.17%) were present or represented by proxy. The results for the three proposals were as follows:
- Proposal 1 (Election of Directors): All three nominees (Patricia Andrews, Mark Goldberg, M.D., and Timothy Pearson) were elected. Broker non-votes totaled 14,198,293.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023.
- Proposal 3 (Executive Compensation): Stockholders approved, on an advisory basis, the executive compensation of the named executive officers. Broker non-votes totaled 14,198,293.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is strictly a report of voting outcomes.
Key Facts for Investor Verification
- Verify the correct registrant name is GlycoMimetics, Inc. (trading symbol: GLYC), not Crescent Biopharma.
- Confirm the election of the three specific director nominees for terms ending in 2026.
- Note the significant number of broker non-votes (14,198,293) on Proposals 1 and 3.
- Review the definitive proxy statement filed on April 21, 2023, for detailed background on the proposals.